| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 76 | 2025 | 2586 | 6.470 |
Why?
|
| Atherosclerosis | 8 | 2023 | 169 | 2.430 |
Why?
|
| Monocytes | 17 | 2024 | 277 | 2.290 |
Why?
|
| Anti-HIV Agents | 19 | 2021 | 486 | 1.950 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 749 | 1.570 |
Why?
|
| Middle Aged | 81 | 2025 | 12222 | 1.470 |
Why?
|
| Inflammation | 12 | 2025 | 758 | 1.440 |
Why?
|
| Male | 97 | 2026 | 23409 | 1.310 |
Why?
|
| Insulin Resistance | 5 | 2020 | 201 | 1.300 |
Why?
|
| Female | 95 | 2026 | 24698 | 1.210 |
Why?
|
| Humans | 122 | 2026 | 43102 | 1.200 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2024 | 247 | 1.130 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 26 | 1.130 |
Why?
|
| Calcium | 3 | 2016 | 491 | 1.090 |
Why?
|
| Body Composition | 7 | 2026 | 159 | 1.090 |
Why?
|
| Anti-Retroviral Agents | 9 | 2020 | 160 | 1.020 |
Why?
|
| Cross-Sectional Studies | 30 | 2025 | 3156 | 0.980 |
Why?
|
| Antiretroviral Therapy, Highly Active | 13 | 2023 | 229 | 0.980 |
Why?
|
| Hawaii | 26 | 2025 | 2011 | 0.960 |
Why?
|
| Albuminuria | 3 | 2016 | 78 | 0.930 |
Why?
|
| HIV-1 | 12 | 2024 | 755 | 0.910 |
Why?
|
| Adult | 57 | 2025 | 13872 | 0.840 |
Why?
|
| Chemokine CCL2 | 2 | 2016 | 95 | 0.820 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 163 | 0.800 |
Why?
|
| Niacin | 3 | 2013 | 23 | 0.790 |
Why?
|
| Vasodilation | 2 | 2015 | 64 | 0.770 |
Why?
|
| Polyneuropathies | 2 | 2013 | 9 | 0.770 |
Why?
|
| Risk Factors | 20 | 2025 | 3994 | 0.760 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 12 | 0.760 |
Why?
|
| Bone Diseases | 2 | 2020 | 18 | 0.720 |
Why?
|
| Carotid Arteries | 2 | 2019 | 36 | 0.720 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 16 | 0.660 |
Why?
|
| Erythrocyte Indices | 2 | 2018 | 14 | 0.650 |
Why?
|
| Cohort Studies | 17 | 2025 | 1759 | 0.640 |
Why?
|
| Cellulitis | 2 | 2010 | 6 | 0.630 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 386 | 0.610 |
Why?
|
| Autonomic Nervous System | 2 | 2012 | 39 | 0.600 |
Why?
|
| Coronary Vessels | 2 | 2019 | 92 | 0.600 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2026 | 94 | 0.580 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 4 | 2019 | 31 | 0.560 |
Why?
|
| Calcinosis | 2 | 2016 | 62 | 0.560 |
Why?
|
| Brachial Artery | 2 | 2015 | 27 | 0.550 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.550 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 539 | 0.530 |
Why?
|
| HIV | 4 | 2020 | 100 | 0.520 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.520 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2024 | 184 | 0.520 |
Why?
|
| Lipoproteins | 3 | 2014 | 70 | 0.520 |
Why?
|
| Whole Body Imaging | 3 | 2021 | 25 | 0.510 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2020 | 201 | 0.500 |
Why?
|
| Vitamin D | 3 | 2016 | 196 | 0.500 |
Why?
|
| Aging | 5 | 2023 | 783 | 0.490 |
Why?
|
| Hepatitis C | 3 | 2022 | 139 | 0.490 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2024 | 279 | 0.490 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2015 | 13 | 0.490 |
Why?
|
| Bilirubin | 1 | 2016 | 18 | 0.480 |
Why?
|
| AIDS Dementia Complex | 4 | 2024 | 116 | 0.470 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.470 |
Why?
|
| Anthropometry | 6 | 2022 | 97 | 0.470 |
Why?
|
| Retrospective Studies | 13 | 2025 | 2544 | 0.470 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 15 | 0.450 |
Why?
|
| Reflex | 2 | 2013 | 29 | 0.420 |
Why?
|
| Body Mass Index | 6 | 2023 | 925 | 0.420 |
Why?
|
| Absorptiometry, Photon | 7 | 2026 | 76 | 0.420 |
Why?
|
| Methicillin Resistance | 2 | 2010 | 12 | 0.410 |
Why?
|
| Plasma | 1 | 2013 | 38 | 0.400 |
Why?
|
| Aged | 22 | 2025 | 8214 | 0.400 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 440 | 0.390 |
Why?
|
| Interleukin-6 | 2 | 2020 | 165 | 0.390 |
Why?
|
| Adipose Tissue | 4 | 2021 | 182 | 0.380 |
Why?
|
| Longitudinal Studies | 6 | 2017 | 1063 | 0.380 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 384 | 0.380 |
Why?
|
| Pilot Projects | 9 | 2026 | 760 | 0.380 |
Why?
|
| Antipruritics | 1 | 2012 | 3 | 0.370 |
Why?
|
| Foot Diseases | 1 | 2012 | 2 | 0.370 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2012 | 14 | 0.360 |
Why?
|
| Capsaicin | 1 | 2012 | 28 | 0.360 |
Why?
|
| Disease Progression | 5 | 2024 | 667 | 0.360 |
Why?
|
| Neuralgia | 1 | 2012 | 22 | 0.350 |
Why?
|
| Vascular Diseases | 1 | 2011 | 33 | 0.350 |
Why?
|
| Viremia | 1 | 2011 | 44 | 0.340 |
Why?
|
| Anus Diseases | 1 | 2011 | 17 | 0.340 |
Why?
|
| Prognosis | 4 | 2019 | 861 | 0.340 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2010 | 10 | 0.330 |
Why?
|
| Heart Rate | 6 | 2017 | 266 | 0.330 |
Why?
|
| Anal Canal | 1 | 2011 | 32 | 0.330 |
Why?
|
| Community-Acquired Infections | 1 | 2010 | 22 | 0.330 |
Why?
|
| Cognition Disorders | 4 | 2013 | 243 | 0.330 |
Why?
|
| Cerebral Cortex | 4 | 2017 | 306 | 0.320 |
Why?
|
| Leukopenia | 1 | 2010 | 10 | 0.320 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 23 | 0.320 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 99 | 0.310 |
Why?
|
| Azetidines | 1 | 2009 | 7 | 0.310 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 67 | 0.310 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 25 | 0.310 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 73 | 0.300 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 42 | 0.300 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 2 | 0.300 |
Why?
|
| Leprosy | 1 | 2009 | 4 | 0.300 |
Why?
|
| Metformin | 2 | 2020 | 75 | 0.300 |
Why?
|
| Weight Loss | 1 | 2010 | 137 | 0.300 |
Why?
|
| Central Nervous System Diseases | 2 | 2019 | 32 | 0.300 |
Why?
|
| beta-Lactams | 1 | 2008 | 2 | 0.290 |
Why?
|
| Mass Screening | 2 | 2011 | 541 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 89 | 0.290 |
Why?
|
| Electrocardiography | 5 | 2017 | 185 | 0.290 |
Why?
|
| Adolescent | 13 | 2026 | 6081 | 0.290 |
Why?
|
| Imidazoles | 2 | 2020 | 142 | 0.280 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2007 | 1 | 0.270 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2007 | 6 | 0.270 |
Why?
|
| Antiviral Agents | 1 | 2010 | 195 | 0.270 |
Why?
|
| Lipoproteins, LDL | 2 | 2020 | 67 | 0.270 |
Why?
|
| DNA, Single-Stranded | 1 | 2007 | 40 | 0.270 |
Why?
|
| Lymphocyte Activation | 5 | 2024 | 249 | 0.260 |
Why?
|
| Cytokines | 5 | 2023 | 678 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2008 | 432 | 0.260 |
Why?
|
| Anemia, Macrocytic | 1 | 2007 | 2 | 0.260 |
Why?
|
| Elastin | 2 | 2006 | 40 | 0.260 |
Why?
|
| Lamivudine | 1 | 2007 | 22 | 0.260 |
Why?
|
| Phenotype | 4 | 2022 | 780 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 245 | 0.250 |
Why?
|
| Acid-Base Imbalance | 1 | 2006 | 3 | 0.250 |
Why?
|
| Lactates | 1 | 2006 | 9 | 0.250 |
Why?
|
| Hypoalbuminemia | 1 | 2006 | 4 | 0.250 |
Why?
|
| Acid-Base Equilibrium | 1 | 2006 | 8 | 0.250 |
Why?
|
| Granulocytes | 2 | 2023 | 26 | 0.250 |
Why?
|
| Oxygen Consumption | 3 | 2017 | 110 | 0.250 |
Why?
|
| Serum Albumin | 1 | 2006 | 59 | 0.240 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2006 | 3 | 0.240 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 8 | 0.240 |
Why?
|
| Headache | 1 | 2006 | 21 | 0.240 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 376 | 0.240 |
Why?
|
| Nanotechnology | 1 | 2007 | 176 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2024 | 587 | 0.240 |
Why?
|
| Receptors, Immunologic | 3 | 2024 | 73 | 0.240 |
Why?
|
| Prevalence | 5 | 2018 | 1612 | 0.240 |
Why?
|
| Complement System Proteins | 1 | 2025 | 25 | 0.230 |
Why?
|
| Blood Coagulation | 1 | 2025 | 29 | 0.230 |
Why?
|
| Temperature | 2 | 2006 | 313 | 0.230 |
Why?
|
| Renin-Angiotensin System | 1 | 2025 | 48 | 0.230 |
Why?
|
| Oligopeptides | 1 | 2006 | 109 | 0.230 |
Why?
|
| Fever | 1 | 2006 | 62 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 38 | 0.230 |
Why?
|
| Mitochondria | 3 | 2020 | 523 | 0.230 |
Why?
|
| Physical Fitness | 2 | 2017 | 90 | 0.230 |
Why?
|
| Pyelonephritis | 1 | 2005 | 3 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 296 | 0.230 |
Why?
|
| Emphysema | 1 | 2005 | 6 | 0.220 |
Why?
|
| Antigens, Viral | 1 | 2024 | 48 | 0.220 |
Why?
|
| Escherichia coli | 3 | 2006 | 460 | 0.220 |
Why?
|
| Double-Blind Method | 3 | 2025 | 317 | 0.220 |
Why?
|
| Viral Load | 4 | 2019 | 348 | 0.210 |
Why?
|
| Myeloid Cells | 2 | 2024 | 31 | 0.210 |
Why?
|
| Time Factors | 5 | 2017 | 1857 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 1 | 2024 | 38 | 0.200 |
Why?
|
| CD4-CD8 Ratio | 3 | 2020 | 29 | 0.200 |
Why?
|
| Young Adult | 9 | 2025 | 5080 | 0.200 |
Why?
|
| Atrophy | 3 | 2024 | 51 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2025 | 1600 | 0.200 |
Why?
|
| Macrophages | 4 | 2020 | 529 | 0.190 |
Why?
|
| Receptors, CCR2 | 2 | 2020 | 28 | 0.190 |
Why?
|
| Delayed-Action Preparations | 3 | 2013 | 74 | 0.190 |
Why?
|
| Neuropsychological Tests | 4 | 2024 | 284 | 0.190 |
Why?
|
| Somatotypes | 1 | 2022 | 4 | 0.190 |
Why?
|
| Benzoxazines | 2 | 2022 | 47 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 226 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 2853 | 0.180 |
Why?
|
| Leukocyte Count | 2 | 2019 | 69 | 0.180 |
Why?
|
| Oxidative Phosphorylation | 2 | 2020 | 60 | 0.180 |
Why?
|
| Cerebrovascular Disorders | 2 | 2012 | 43 | 0.180 |
Why?
|
| Comorbidity | 3 | 2016 | 737 | 0.170 |
Why?
|
| Gonorrhea | 1 | 2021 | 24 | 0.170 |
Why?
|
| Hospitalization | 2 | 2014 | 485 | 0.170 |
Why?
|
| Cognition | 3 | 2014 | 473 | 0.160 |
Why?
|
| Hippocampus | 2 | 2016 | 594 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 193 | 0.160 |
Why?
|
| RNA, Viral | 3 | 2020 | 321 | 0.160 |
Why?
|
| Hyponatremia | 1 | 2020 | 6 | 0.160 |
Why?
|
| HIV Seropositivity | 4 | 2014 | 196 | 0.160 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.160 |
Why?
|
| DNA, Mitochondrial | 3 | 2019 | 191 | 0.160 |
Why?
|
| Sodium Chloride | 1 | 2020 | 54 | 0.160 |
Why?
|
| Knee | 1 | 2019 | 7 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 18 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 117 | 0.160 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 174 | 0.150 |
Why?
|
| Hypertension | 2 | 2003 | 835 | 0.150 |
Why?
|
| Triazoles | 2 | 2023 | 102 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 60 | 0.150 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.150 |
Why?
|
| Lipoproteins, HDL | 2 | 2019 | 48 | 0.150 |
Why?
|
| E-Selectin | 1 | 2018 | 23 | 0.140 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 206 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2019 | 171 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 83 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 36 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 502 | 0.130 |
Why?
|
| Cell Respiration | 1 | 2017 | 35 | 0.130 |
Why?
|
| Diverticulum | 1 | 1997 | 2 | 0.130 |
Why?
|
| Jejunum | 1 | 1997 | 7 | 0.130 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 57 | 0.130 |
Why?
|
| Ileum | 1 | 1997 | 20 | 0.130 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 518 | 0.120 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 1996 | 1 | 0.120 |
Why?
|
| Nerve Net | 1 | 2017 | 101 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 1604 | 0.120 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 13 | 0.120 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 26 | 0.120 |
Why?
|
| Biopsy | 3 | 2011 | 177 | 0.120 |
Why?
|
| Hepacivirus | 2 | 2022 | 74 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2017 | 187 | 0.120 |
Why?
|
| Brain | 1 | 2024 | 1472 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 36 | 0.120 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.120 |
Why?
|
| Amblyopia | 1 | 2015 | 13 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2016 | 549 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 164 | 0.120 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 97 | 0.110 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.110 |
Why?
|
| Blood Glucose | 5 | 2020 | 389 | 0.110 |
Why?
|
| Subcutaneous Fat | 2 | 2019 | 19 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2018 | 329 | 0.110 |
Why?
|
| HIV-2 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 1996 | 140 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 167 | 0.110 |
Why?
|
| Blood Platelets | 2 | 2025 | 81 | 0.110 |
Why?
|
| Blood Pressure | 4 | 2013 | 666 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 13 | 0.100 |
Why?
|
| Neutrophils | 2 | 2025 | 145 | 0.100 |
Why?
|
| Social Work | 1 | 2013 | 53 | 0.100 |
Why?
|
| Dementia | 1 | 2014 | 160 | 0.100 |
Why?
|
| Cholesterol | 1 | 2014 | 232 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 79 | 0.100 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 11 | 0.090 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 22 | 0.090 |
Why?
|
| Bacteremia | 1 | 2012 | 37 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2016 | 1003 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2012 | 48 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.090 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2019 | 57 | 0.090 |
Why?
|
| Acne Vulgaris | 1 | 2011 | 7 | 0.090 |
Why?
|
| Cacao | 1 | 2011 | 10 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2013 | 311 | 0.090 |
Why?
|
| Arteries | 1 | 2011 | 81 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 692 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2012 | 183 | 0.080 |
Why?
|
| Receptors, IgG | 3 | 2016 | 53 | 0.080 |
Why?
|
| Incidence | 2 | 2011 | 1078 | 0.080 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 14 | 0.080 |
Why?
|
| Cyclopropanes | 2 | 2022 | 46 | 0.080 |
Why?
|
| Alkynes | 2 | 2022 | 52 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 16 | 0.080 |
Why?
|
| Puerto Rico | 2 | 2025 | 1413 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2010 | 15 | 0.080 |
Why?
|
| Ribavirin | 1 | 2010 | 21 | 0.080 |
Why?
|
| World Health Organization | 1 | 2010 | 36 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2010 | 43 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 611 | 0.080 |
Why?
|
| Genotype | 2 | 2010 | 800 | 0.080 |
Why?
|
| Papillomaviridae | 1 | 2011 | 142 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 67 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 104 | 0.080 |
Why?
|
| HLA-DR Antigens | 2 | 2022 | 23 | 0.080 |
Why?
|
| Sulfoxides | 2 | 2020 | 18 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 153 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 115 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 108 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 234 | 0.070 |
Why?
|
| Fibrosis | 2 | 2022 | 169 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 590 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 301 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1621 | 0.070 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2007 | 3 | 0.070 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2007 | 4 | 0.070 |
Why?
|
| Thymine Nucleotides | 1 | 2007 | 4 | 0.070 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2007 | 20 | 0.070 |
Why?
|
| Sympathetic Fibers, Postganglionic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Sweat Glands | 1 | 2007 | 3 | 0.070 |
Why?
|
| Sweating | 1 | 2007 | 5 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2009 | 178 | 0.070 |
Why?
|
| United States | 3 | 2025 | 5205 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2007 | 76 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 118 | 0.070 |
Why?
|
| Oligonucleotides | 1 | 2007 | 49 | 0.070 |
Why?
|
| Microscopy, Atomic Force | 1 | 2007 | 61 | 0.070 |
Why?
|
| Surface Plasmon Resonance | 1 | 2007 | 42 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2007 | 40 | 0.070 |
Why?
|
| Antibodies | 1 | 2007 | 144 | 0.070 |
Why?
|
| Surface Properties | 1 | 2007 | 160 | 0.060 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2006 | 35 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 31 | 0.060 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 6 | 0.060 |
Why?
|
| Lipodystrophy | 1 | 2006 | 7 | 0.060 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 64 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2006 | 95 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 49 | 0.060 |
Why?
|
| Critical Illness | 1 | 2006 | 47 | 0.060 |
Why?
|
| Tilt-Table Test | 1 | 2006 | 4 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 211 | 0.060 |
Why?
|
| Angiotensin I | 1 | 2025 | 9 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2006 | 48 | 0.060 |
Why?
|
| Platelet Activation | 1 | 2025 | 6 | 0.060 |
Why?
|
| Cell Count | 1 | 2006 | 145 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2025 | 30 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2025 | 10 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 201 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2025 | 41 | 0.060 |
Why?
|
| Lactic Acid | 1 | 2006 | 112 | 0.060 |
Why?
|
| Proteins | 1 | 2008 | 382 | 0.060 |
Why?
|
| Age Factors | 2 | 2014 | 1154 | 0.060 |
Why?
|
| Respiration | 1 | 2006 | 56 | 0.060 |
Why?
|
| Sex Factors | 2 | 2025 | 1028 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 209 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 152 | 0.060 |
Why?
|
| Amino Acids | 1 | 2006 | 148 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 238 | 0.060 |
Why?
|
| Nitrogen | 1 | 2006 | 84 | 0.060 |
Why?
|
| Drainage | 1 | 2005 | 12 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 7 | 0.060 |
Why?
|
| Pregnancy | 1 | 2011 | 1772 | 0.060 |
Why?
|
| Carbon | 1 | 2006 | 128 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 93 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2005 | 30 | 0.060 |
Why?
|
| Child | 2 | 2026 | 3443 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 1081 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 695 | 0.050 |
Why?
|
| Propensity Score | 1 | 2024 | 59 | 0.050 |
Why?
|
| Hemostasis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 210 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 257 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 24 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 719 | 0.050 |
Why?
|
| Galectin 3 | 1 | 2023 | 30 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2025 | 307 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 16 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 61 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 80 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2019 | 1546 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 115 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 147 | 0.050 |
Why?
|
| Vaccination | 1 | 2025 | 355 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2024 | 206 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 183 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 33 | 0.050 |
Why?
|
| Peptides | 1 | 2006 | 372 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 100 | 0.050 |
Why?
|
| Neopterin | 1 | 2022 | 13 | 0.050 |
Why?
|
| ROC Curve | 1 | 2022 | 159 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2022 | 90 | 0.050 |
Why?
|
| Histones | 1 | 2023 | 197 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 240 | 0.050 |
Why?
|
| Vietnam | 1 | 2022 | 62 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 164 | 0.040 |
Why?
|
| Mentors | 1 | 2023 | 145 | 0.040 |
Why?
|
| Exercise Test | 2 | 2014 | 74 | 0.040 |
Why?
|
| Patient Participation | 1 | 2002 | 94 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2002 | 341 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 113 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2014 | 490 | 0.040 |
Why?
|
| Fusobacteria | 1 | 2020 | 4 | 0.040 |
Why?
|
| Japan | 2 | 2014 | 348 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 317 | 0.040 |
Why?
|
| Autoantigens | 1 | 2021 | 87 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 56 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 37 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2020 | 74 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 75 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 511 | 0.040 |
Why?
|
| Quality of Life | 1 | 2025 | 616 | 0.040 |
Why?
|
| Obesity | 2 | 2023 | 1151 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 259 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 203 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 147 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 1234 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 209 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 127 | 0.030 |
Why?
|
| Colitis, Ischemic | 1 | 1997 | 1 | 0.030 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1997 | 4 | 0.030 |
Why?
|
| Pacific Islands | 1 | 2018 | 123 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 258 | 0.030 |
Why?
|
| Minority Groups | 1 | 2023 | 690 | 0.030 |
Why?
|
| Aorta | 1 | 2018 | 198 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1997 | 27 | 0.030 |
Why?
|
| Radiography | 1 | 1997 | 71 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1997 | 173 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2010 | 246 | 0.030 |
Why?
|
| Esophageal Diseases | 1 | 1996 | 4 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 1996 | 7 | 0.030 |
Why?
|
| Ulcer | 1 | 1996 | 6 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 48 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 486 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 233 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 1994 | 11 | 0.030 |
Why?
|
| Thailand | 1 | 1994 | 51 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 224 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1994 | 121 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 70 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 272 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 91 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 32 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1994 | 129 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 356 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 218 | 0.030 |
Why?
|
| Zidovudine | 1 | 2013 | 32 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 1994 | 175 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 532 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 195 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 139 | 0.020 |
Why?
|
| APACHE | 1 | 2012 | 6 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 259 | 0.020 |
Why?
|
| Students, Medical | 1 | 1994 | 158 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 27 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1175 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 986 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 863 | 0.020 |
Why?
|
| Health Education | 1 | 1994 | 363 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2011 | 56 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 159 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 174 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 339 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2010 | 19 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1285 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 655 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2009 | 9 | 0.020 |
Why?
|
| Spirometry | 1 | 2009 | 40 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 259 | 0.020 |
Why?
|
| Bacteria | 1 | 2012 | 293 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 152 | 0.020 |
Why?
|
| Glucose | 1 | 2010 | 244 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 123 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 74 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 452 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 455 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2006 | 64 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2006 | 39 | 0.020 |
Why?
|
| Philippines | 1 | 2006 | 81 | 0.020 |
Why?
|
| Introns | 1 | 2006 | 79 | 0.020 |
Why?
|
| Axons | 1 | 2007 | 117 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2006 | 93 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2006 | 26 | 0.020 |
Why?
|
| Autoradiography | 1 | 2006 | 37 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 34 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2006 | 206 | 0.020 |
Why?
|
| Culture Media | 1 | 2006 | 96 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2006 | 197 | 0.020 |
Why?
|
| Drug Stability | 1 | 2006 | 129 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 240 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2006 | 75 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2006 | 587 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 734 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2003 | 67 | 0.010 |
Why?
|
| Systole | 1 | 2000 | 67 | 0.010 |
Why?
|
| Diastole | 1 | 2000 | 47 | 0.010 |
Why?
|